Abstract
Brain neurons containing the neurotransmitter dopamine have two well-characterized functions: they are key regulators of movements, and they mediate reward and motivation induced by natural rewards such as food and sex but also by drugs of abuse including nicotine, alcohol, and illegal drugs [1]. Dopamine neurons from the midbrain and histamine neurons from the posterolateral hypothalamus both send their axons to a brain area called the striatum which is the center for the control of movements, reward, and motivation. The striatum is divided into two subregions: the dorsal striatum which is classically referred to as the motor control region and the ventral striatum, including the nucleus accumbens, which regulates reward and motivation. Recent evidence shows however that the classical division of striatal functions is not that clear and, e.g., dorsal striatal areas have been shown to be involved in the regulation of reward too. The midbrain areas where dopaminergic neuron somas are located, substantia nigra and ventral tegmental area, also receive histaminergic projections [2, 3]. Of importance, the striatum expresses a high density of histamine H1–H3 receptors [4–6] suggesting that histamine can directly affect striatal function and basal ganglia output. The expression of the histamine H3 receptor in the striatum is exceptionally high [5–7]. H3 receptors are G protein-coupled receptors that regulate the release of histamine but also other neurotransmitter release (e.g., GABA, noradrenaline, acetylcholine, and possibly dopamine) [8]. Importantly, majority of the H3 receptors in the striatum are located postsynaptically at GABAergic medium spiny neurons [5, 6, 9], and there is evidence of a direct interaction between H3 and dopamine receptors in co-expressing culture systems [10–12] and in vivo [13].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Trudeau LE, Hnasko TS, Wallen-Mackenzie A, et al. The multilingual nature of dopamine neurons. Prog Brain Res. 2014;211:141–64. doi:10.1016/B978-0-444-63425-2.00006-4.
Airaksinen MS, Panula P. The histaminergic system in the guinea pig central nervous system: an immunocytochemical mapping study using an antiserum against histamine. J Comp Neurol. 1988;273(2):163–86. doi:10.1002/cne.902730204.
Takagi H, Morishima Y, Matsuyama T, et al. Histaminergic axons in the neostriatum and cerebral cortex of the rat: a correlated light and electron microscopic immunocytochemical study using histidine decarboxylase as a marker. Brain Res. 1986;364(1):114–23.
Martinez-Mir MI, Pollard H, Moreau J, et al. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res. 1990;526(2):322–7.
Pillot C, Heron A, Cochois V, et al. A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience. 2002;14(1):173–93.
Pillot C, Ortiz J, Heron A, et al. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J Neurosci. 2002;22(16):7272–80.
Panula P, Nuutinen S. The histaminergic network in the brain: basic organization and role in disease. Nat Rev Neurosci. 2013;14(7):472–87. doi:10.1038/nrn3526.
Ellenbroek BA. Histamine H(3) receptors, the complex interaction with dopamine and its implications for addiction. Br J Pharmacol. 2013;170(1):46–57. doi:10.1111/bph.12221.
Pillot C, Heron A, Schwartz JC, et al. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. Eur J Neurosci. 2003;17(2):307–14.
Ferrada C, Ferre S, Casado V, et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology. 2008;55(2):190–7. doi:10.1016/j.neuropharm.2008.05.008.
Ferrada C, Moreno E, Casado V, et al. Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol. 2009;157(1):64–75. doi:10.1111/j.1476-5381.2009.00152.x.
Moreno E, Moreno-Delgado D, Navarro G, et al. Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine’s effects. J Neurosci. 2014;34(10):3545–58. doi:10.1523/JNEUROSCI.4147-13.2014.
Moreno E, Hoffmann H, Gonzalez-Sepulveda M, et al. Dopamine D1-histamine H3 receptor heteromers provide a selective link to the map-kinase signalling in gabaergic neurons of the direct striatal pathway. J Biol Chem. 2011;286:5846–54. doi:10.1074/jbc.M110.161489.
Nuutinen S, Karlstedt K, Aitta-Aho T, et al. Histamine and H3 receptor-dependent mechanisms regulate ethanol stimulation and conditioned place preference in mice. Psychopharmacology (Berl). 2010;208(1):75–86. doi:10.1007/s00213-009-1710-5.
Nuutinen S, Lintunen M, Vanhanen J, et al. Evidence for the role of histamine H3 receptor in alcohol consumption and alcohol reward in mice. Neuropsychopharmacology. 2011;36(10):2030–40. doi:10.1038/npp.2011.90.
Nuutinen S, Maki T, Rozov S, et al. Histamine H3 receptor antagonist decreases cue-induced alcohol reinstatement in mice. Neuropharmacology. 2015;106:156–63. doi:10.1016/j.neuropharm.2015.06.006.
Nuutinen S, Vanhanen J, Pigni MC, et al. Effects of histamine H3 receptor ligands on the rewarding, stimulant and motor-impairing effects of ethanol in DBA/2J mice. Neuropharmacology. 2011;60(7–8):1193–9. doi:10.1016/j.neuropharm.2010.10.027.
Panula P, Nuutinen S. Histamine and H3 receptor in alcohol-related behaviors. J Pharmacol Exp Ther. 2011;336(1):9–16. doi:10.1124/jpet.110.170928.
Vanhanen J, Nuutinen S, Lintunen M, et al. Histamine is required for H3 receptor-mediated alcohol reward inhibition, but not for alcohol consumption or stimulation. Br J Pharmacol. 2013;170(1):177–87. doi:10.1111/bph.12170.
Bolam JP, Ellender TJ. Histamine and the striatum. Neuropharmacology. 2015;106:74–84. doi:10.1016/j.neuropharm.2015.08.013.
Bristow LJ, Bennett GW. Biphasic effects of intra-accumbens histamine administration on spontaneous motor activity in the rat; a role for central histamine receptors. Br J Pharmacol. 1988;95(4):1292–302.
Chiavegatto S, Nasello AG, Bernardi MM. Histamine and spontaneous motor activity: biphasic changes, receptors involved and participation of the striatal dopamine system. Life Sci. 1998;62(20):1875–88.
Kalivas PW. Histamine-induced arousal in the conscious and pentobarbital-pretreated rat. J Pharmacol Exp Ther. 1982;222(1):37–42.
Alvarez EO. Banzan AM Further evidence that histamine in hippocampus affects the exploratory behavior in the rat. Physiol Behav. 1985;34(5):661–4.
Inoue I, Yanai K, Kitamura D, et al. Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci U S A. 1996;93(23):13316–20.
Alvarez EO, Banzan AM. Histamine in dorsal and ventral hippocampus. II. Effects of H1 and H2 histamine antagonists on exploratory behavior in male rats. Physiol Behav. 1986;37(1):39–45.
Iwabuchi K, Kubota Y, Ito C, et al. Methamphetamine and brain histamine: a study using histamine-related gene knockout mice. Ann N Y Acad Sci. 2004;1025:129–34. doi:10.1196/annals.1316.016.
Brabant C, Charlier Y, Quertemont E, et al. The H3 antagonist thioperamide reveals conditioned preference for a context associated with an inactive small dose of cocaine in C57BL/6J mice. Behav Brain Res. 2005;160(1):161–8. doi:10.1016/j.bbr.2004.11.029.
Zhang M, Ballard ME, Pan L, et al. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res. 2005;1045(1–2):142–9.
Akhtar M, Uma Devi P, Ali A, et al. Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice. Fundam Clin Pharmacol. 2006;20(4):373–8.
Liu CQ, Chen Z, Liu FX, et al. Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats. Neuropharmacology. 2007;53(7):832–41.
Liu CQ, Hu DN, Liu FX, et al. Apomorphine-induced turning behavior in 6-hydroxydopamine lesioned rats is increased by histidine and decreased by histidine decarboxylase, histamine H1 and H2 receptor antagonists, and an H3 receptor agonist. Pharmacol Biochem Behav. 2008;90(3):325–30. doi:10.1016/j.pbb.2008.03.010.
Garcia-Ramirez M, Aceves J, Arias-Montano JA. Intranigral injection of the H3 agonist immepip and systemic apomorphine elicit ipsilateral turning behaviour in naive rats, but reduce contralateral turning in hemiparkinsonian rats. Behav Brain Res. 2004;54(2):409–15. doi:10.1016/j.bbr.2004.03.007.
Huotari M, Kukkonen K, Liikka N, et al. Effects of histamine H(3)-ligands on the levodopa-induced turning behavior of hemiparkinsonian rats. Parkinsonism Relat Disord. 2000;6(3):159–64.
Nowak P, Bortel A, Dabrowska J, et al. Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum. Neurotox Res. 2008;13(3–4):231–40.
Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217–38. doi:10.1038/npp.2009.110.
Cohn CK, Ball GG, Hirsch J. Histamine: effect on self-stimulation. Science. 1973;180(87):757–8.
Suzuki T, Takamori K, Misawa M, et al. Effects of the histaminergic system on the morphine-induced conditioned place preference in mice. Brain Res. 1995;675(1–2):195–202.
Masukawa Y, Suzuki T, Misawa M. Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines. Psychopharmacology (Berl). 1993;111(2):139–43.
Suzuki T, Mori T, Tsuji M, et al. Generalization of D-, L- and DL-chlorpheniramine and zolantidine to the discriminative stimulus effects of cocaine and methamphetamine. Behav Pharmacol. 1997;8(8):718–24.
Takino N, Sakurai E, Kuramasu A, et al. Roles of the histaminergic neurotransmission on methamphetamine-induced locomotor sensitization and reward: a study of receptors gene knockout mice. Int Rev Neurobiol. 2009;85:109–16. doi:10.1016/S0074-7742(09)85008-3.
Okuda T, Ito Y, Nakagawa N, et al. Drug interaction between methamphetamine and antihistamines: behavioral changes and tissue concentrations of methamphetamine in rats. Eur J Pharmacol. 2004;505(1–3):135–44. doi:10.1016/j.ejphar.2004.10.022.
Brabant C, Alleva L, Grisar T, et al. Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology (Berl). 2009;202(4):673–87. doi:10.1007/s00213-008-1345-y.
Brabant C, Quertemont E, Anaclet C, et al. The psychostimulant and rewarding effects of cocaine in histidine decarboxylase knockout mice do not support the hypothesis of an inhibitory function of histamine on reward. Psychopharmacology (Berl). 2007;190(2):251–63. doi:10.1007/s00213-006-0603-0.
Aquino-Miranda G, Escamilla-Sanchez J, Gonzalez-Pantoja R, et al. Histamine H receptor activation inhibits dopamine synthesis but not release or uptake in rat nucleus accumbens. Neuropharmacology. 2015;106:91–101. doi:10.1016/j.neuropharm.2015.07.006.
Anichtchik OV, Huotari M, Peitsaro N, et al. Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats. Eur J Neurosci. 2000;12(11):3823–32.
Anichtchik OV, Peitsaro N, Rinne JO, et al. Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson’s disease. Neurobiol Dis. 2001;8(4):707–16. doi:10.1006/nbdi.2001.0413.
Anichtchik OV, Rinne JO, Kalimo H, et al. An altered histaminergic innervation of the substantia nigra in Parkinson’s disease. Exp Neurol. 2000;163(1):20–30. doi:10.1006/exnr.2000.7362.
Gonzalez-Sepulveda M, Rosell S, Hoffmann HM, et al. Cellular distribution of the histamine H3 receptor in the basal ganglia: functional modulation of dopamine and glutamate neurotransmission. Basal Ganglia. 2013;3:109–21.
Onali P, Olianas MC. Involvement of adenylate cyclase inhibition in dopamine autoreceptor regulation of tyrosine hydroxylase in rat nucleus accumbens. Neurosci Lett. 1989;102(1):91–6.
Molina-Hernandez A, Nunez A, Arias-Montano JA. Histamine H3-receptor activation inhibits dopamine synthesis in rat striatum. Neuroreport. 2000;11(1):163–6.
Castellan Baldan L, Williams KA, Gallezot JD, et al. Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. Neuron. 2014;81(1):77–90. doi:10.1016/j.neuron.2013.10.052.
Rapanelli M, Pittenger C. Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions. Neuropharmacology. 2015;106:85–90. doi:10.1016/j.neuropharm.2015.08.019.
Dere E, De Souza-Silva MA, Topic B, et al. Histidine-decarboxylase knockout mice show deficient nonreinforced episodic object memory, improved negatively reinforced water-maze performance, and increased neo- and ventro-striatal dopamine turnover. Learn Mem. 2003;10(6):510–9. doi:10.1101/lm.67603.
Ercan-Sencicek AG, Stillman AA, Ghosh AK, et al. L-histidine decarboxylase and Tourette’s syndrome. N Engl J Med. 2010;20;362(20):1901–8. doi:10.1056/NEJMoa0907006.
Escobedo-Avila I, Vargas-Romero F, Molina-Hernandez A, et al. Histamine impairs midbrain dopaminergic development in vivo by activating histamine type 1 receptors. Mol Brain. 2014;7:58. doi:10.1186/s13041-014-0058-x.
Vizuete ML, Merino M, Venero JL, et al. Histamine infusion induces a selective dopaminergic neuronal death along with an inflammatory reaction in rat substantia nigra. J Neurochem. 2000;75(2):540–52.
Rinne JO, Anichtchik OV, Eriksson KS, et al. Increased brain histamine levels in Parkinson’s disease but not in multiple system atrophy. J Neurochem. 2002;81(5):954–60.
Korotkova TM, Haas HL, Brown RE. Histamine excites GABAergic cells in the rat substantia nigra and ventral tegmental area in vitro. Neurosci Lett. 2002;320(3):133–6.
Zhou FW, Xu JJ, Zhao Y, et al. Opposite functions of histamine H1 and H2 receptors and H3 receptor in substantia nigra pars reticulata. J Neurophysiol. 2006;96(3):1581–91.
Schlicker E, Fink K, Detzner M, et al. Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J Neural Transm Gen Sect. 1993;93(1):1–10.
Pollard H, Moreau J, Arrang JM, et al. A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience. 1993;52(1):169–89.
Sanchez-Lemus E, Arias-Montano JA. Histamine H3 receptor activation inhibits dopamine D1 receptor-induced cAMP accumulation in rat striatal slices. Neurosci Lett. 2004;364(3):179–84. doi:10.1016/j.neulet.2004.04.045.
Clapham J, Kilpatrick GJ. Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur J Pharmacol. 1994;259(2):107–14.
Fox GB, Esbenshade TA, Pan JB, et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther. 2005;313(1):176–90. doi:10.1124/jpet.104.078402.
Morisset S, Pilon C, Tardivel-Lacombe J, et al. Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: selective involvement of the D(2) and not D(3) receptor. J Pharmacol Exp Ther. 2002;300(2):621–8.
Toyota H, Dugovic C, Koehl M, et al. Behavioral characterization of mice lacking histamine H(3) receptors. Mol Pharmacol. 2002;62(2):389–97.
Southam E, Cilia J, Gartlon JE, et al. Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology (Berl). 2009;201(4):483–94. doi:10.1007/s00213-008-1310-9.
Ligneau X, Perrin D, Landais L, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther. 2007;320(1):365–75. doi:10.1124/jpet.106.111039.
Vanhanen J, Kinnunen M, Nuutinen S, et al. Histamine H3 receptor antagonist JNJ-39220675 modulates locomotor responses but not place conditioning by dopaminergic drugs. Psychopharmacology (Berl). 2015;232(6):1143–53. doi:10.1007/s00213-014-3751-7.
Cousins V, Rose JE, Levin ED. IV nicotine self-administration in rats using a consummatory operant licking response: sensitivity to serotonergic, glutaminergic and histaminergic drugs. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:200–5. doi:10.1016/j.pnpbp.2014.06.004.
Levin ED, Slade S, Wells C, et al. Histamine H(1) antagonist treatment with pyrilamine reduces nicotine self-administration in rats. Eur J Pharmacol. 2011;650(1):256–60. doi:10.1016/j.ejphar.2010.10.013.
Munzar P, Tanda G, Justinova Z, et al. Histamine h3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release. Neuropsychopharmacology. 2004;29(4):705–17. doi:10.1038/sj.npp.1300380.
Lintunen M, Hyytia P, Sallmen T, et al. Increased brain histamine in an alcohol-preferring rat line and modulation of ethanol consumption by H(3) receptor mechanisms. FASEB J. 2001;15(6):1074–6.
Okuda T, Zhang D, Shao H, et al. Methamphetamine- and 3,4-methylenedioxymethamphetamine-induced behavioral changes in histamine H3-receptor knockout mice. J Pharmacol Sci. 2009;111(2):167–74.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Nuutinen, S., Salminen, O. (2016). Interaction of Brain Histaminergic and Dopaminergic Systems. In: Blandina, P., Passani, M. (eds) Histamine Receptors. The Receptors, vol 28. Humana, Cham. https://doi.org/10.1007/978-3-319-40308-3_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-40308-3_12
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-319-40306-9
Online ISBN: 978-3-319-40308-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)